Part 2. Imatinib for Gastrointestinal Stromal Tumors (GISTs) (continued)

Included Articles

1. Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. Journal of Nuclear Medicine 2004;45(3):357-65.

2. Blay J-Y, Berthaud P, Perol D, et al. Continuous vs intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French Sarcoma Group. Journal of Clinical Oncology 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S (July 15 Supplement)): 9006 2004.

3. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. British Journal of Cancer 2003;89(3):460-4.

4. Casali PG, Fumagalli E, Messina A, et al. Tumor response to imatinib mesylate in advanced GIST. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S (July 15 Supplement)):9028 2004.

5. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clinical Cancer Research 2002;8(10):3034-8.

6. De Giorgi U, Aliberti C, Benea G, et al. Effect of angio-echography with a second-generation contrast agent to assess tumor response to imatinib treatment in patients with advanced gastrointestinal stromal tumor (GIST): Comparison with computerized tomography (CT). Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S (July 15 Supplement)):4216 2004.

7. Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 2004;40(5):689-95.

8. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New England Journal of Medicine 2002;347(7):472-80.

9. Frolov A, Chahwan S, Ochs M, et al. Response markers and the molecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Molecular Cancer Therapeutics 2003;2(8):699-709.

10. Gayed I, Vu T, Iyer R, et al. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. Journal of Nuclear Medicine 2004;45(1):17-21.

11. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. Journal of Clinical Oncology 2003;21(23):4342-9.

12. Lassau N, Lamuraglia M, Leclère J, et al. Doppler-Ultrasonography with perfusion software and contrast medium injection as an early evaluation tool of gastro intestinal stromal tumor (GIST) treated by imatinib: results of a prospective study. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22 (14S (July 15 Supplement)):9048.

13. Patel SR. Early results from randomized phase III trial of imatinib mesylate for gastrointestinal stromal tumors. Current Oncology Reports 2003;5(4):273.

14. Rankin C, Von Mehren M, Blanke C, et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST—Phase III Sarcoma Group Study S0033. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22(14S (July 15 Supplement)): 9005 2004.

15. Rutkowski P, Nyckowski P, Grzesiakowska U, et al. The clinical characteristics and the role of surgery and imatinib treatment in patients with liver metastases from c-Kit positive gastrointestinal stromal tumors (GIST). Neoplasma 2003;50(6):438-42.

16. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? American Journal of Surgery 2003;186(6):665-9.

17. Stroobants S, Goeminne J, Seegers M, et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). European Journal of Cancer 2003;39(14):2012-30.

18. van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-3.

19. van Oosterom AT, Judson IR, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. European Journal of Cancer 2002;38(Suppl 5):S83-7.

20. Verweij J, Casali PB, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34.

21. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. European Journal of Cancer 2003;39(14):2006-11.

22. Wu PC, Langerman A, Ryan CW, et al. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery 2003;134(4):656-66.

23. Zalcberg JR, Verweij J, Casali PG, et al. Outcome of patients with advanced gastro-intestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800mg (HD) after progression on 400mg (LD)—an international, intergroup study of the EORTC, ISG and AGITG. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004;22(14S (July 15 Supplement)):9004 2004.

Return to Contents

Excluded Articles

1. Bono P, Krause A, von Mehren M, et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004;103(8):2929-35.

2. Cho H, Tsuburaya A, Kobayashi O, et al. A risk estimation with tumor size, serosal invasion and MIB-1 labeling index for gastrointestinal stromal tumor (GIST) of the stomach. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22(14S (July 15 Supplement)): 9025 2004.

3. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours [Review]. British Journal of Surgery 2003;90(10):1178-86.

4. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours [Review]. Drugs 2003;63(5):513-4.

5. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy [Review]. Seminars in Hematology 2003;40(2 Suppl 2):21-5.

6. Katz D, Segal A, Alberton Y, et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anti-Cancer Drugs 2004;15(6):599-602.

7. National Horizon Scanning Centre.  Imatinib for gastro-intestinal stromal tumours. Birmingham, UK: National Horizon Scanning Centre (NHSC), 2002. New and Emerging Technology Briefing.

8. National Institute for Clinical Excellence. Imatinib for gastro-intestinal stromal tumours—appraisal (project). London: National Institute for Clinical Excellence (NICE), 2004.

9. Ricci R, Maggiano N, Castri F, et al. Role of PTEN in gastrointestinal stromal tumor progression. Archives of Pathology & Laboratory Medicine 2004;128(4):421-5.

10. Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL) treated with imatinib. Blood 2004;103(4):1495-8.

11. Wilson JS, Connock M, Song FJ, et al. Imatinib mesylate for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours (GIST). Birmingham: West Midlands Health Technology Assessment Collaboration, University of Birmingham, October 2003.

1. Bono P, Krause A, von Mehren M, et al. Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib. Blood 2004;103(8):2929-35.

2. Cho H, Tsuburaya A, Kobayashi O, et al. A risk estimation with tumor size, serosal invasion and MIB-1 labeling index for gastrointestinal stromal tumor (GIST) of the stomach. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 2004; 22(14S (July 15 Supplement)): 9025 2004.

3. Connolly EM, Gaffney E, Reynolds JV. Gastrointestinal stromal tumours [Review]. British Journal of Surgery 2003;90(10):1178-86.

4. Croom KF, Perry CM. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours [Review]. Drugs 2003;63(5):513-4.

5. Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy [Review]. Seminars in Hematology 2003;40(2 Suppl 2):21-5.

6. Katz D, Segal A, Alberton Y, et al. Neoadjuvant imatinib for unresectable gastrointestinal stromal tumor. Anti-Cancer Drugs 2004;15(6):599-602.

7. National Horizon Scanning Centre.  Imatinib for gastro-intestinal stromal tumours. Birmingham, UK: National Horizon Scanning Centre (NHSC), 2002. New and Emerging Technology Briefing.

8. Ricci R, Maggiano N, Castri F, et al. Role of PTEN in gastrointestinal stromal tumor progression. Archives of Pathology & Laboratory Medicine 2004;128(4):421-5.

9. Wassmann B, Pfeifer H, Scheuring UJ, et al. Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph⁺ ALL) treated with imatinib. Blood 2004;103(4):1495-8.

10. Wilson JS, Connock M, Song FJ, et al. Imatinib mesylate for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours (GIST). Birmingham: West Midlands Health Technology Assessment Collaboration, University of Birmingham, October 2003.

Return to Contents
Proceed to Next Section